VelcadeŽ (bortezomib) is an injectable anti-cancer agent used in various stages of multiple myeloma. See potential side effects and other information.
People also ask
What is the success rate of bortezomib?
Is bortezomib chemo?
Do you lose your hair with bortezomib?
How does bortezomib treat multiple myeloma?
Bortezomib is the first proteasome inhibitor to be approved for the treatment of myeloma and represents a step forward in the management of these patients.
Bortezomib is FDA-approved for use in the initial treatment of multiple myeloma in combination with cyclophosphamide and dexamethasone.
Sep 1, 2023 ˇ Bortezomib is a type of targeted cancer drug. It is also known as Velcade. It is a treatment for myeloma and mantle cell lymphoma.
Mar 22, 2024 ˇ Induction regimens for multiple myeloma (MM) commonly include bortezomib, which has typically been administered twice weekly despite studies ...
Jun 30, 2014 ˇ VelcadeŽ represents a new type of anticancer drug called proteasome inhibitors. It has shown promise in the treatment of multiple myeloma, ...
This Treatment Guide contains information about bortezomib (VelcadeŽ), a drug used in the treatment of myeloma.
An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients
Long-term outcomes appeared similar: 3-year progression-free survival rate was 50% in the once-weekly and 47% in the twice-weekly group (P > .999), and 3-year ...
... cancer. Giving isatuximab, lenalidomide, bortezomib, and dexamethasone may help treat patients with multiple myeloma. Location: 2 locations. A Study ...
People also search for
